TrialThe oncologist2024

Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.

Zhiwei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.